DW6014
Asset
Selective SGLT2 inhibitor blocking renal glucose reabsorption.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- SLC5A2
- 1
- Indication
- 1,598
- Trials
- 1
- Developer
Indications
1Dw6014
Phase 1, Unknown, NCT05823883, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1,598
- Evidence for its targets3
- Competitors12
- Aging relevance2
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.